INDPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Indaptus Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.73+0.10 (+3.80%)
Close on Oct 19, 2026
- Market cap
- $317.04M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.3%
0M of 133M shares
Institutional holders
9
6 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Yao Yun | 41,991,000 | 31.51% | 13D (active) amendment | Jun 24, 2026 |
| Sino Lion Ventures Ltd | 38,895,000 | 29.19% | 13D (active) amendment | Jun 24, 2026 |
| Jeffery A. Meckler | 273,103 | 12.70% | 13D (active) amendment | Dec 22, 2025 |
| Lazar David E. | 2,064,000 | 47.93% | 13D (active) amendment | Mar 23, 2026 |
| Newman Michael James | 115,552 | 5.40% | 13D (active) amendment | Dec 22, 2025 |
| Yang Ting | 11,250,000 | 8.44% | 13D (active) amendment | Jun 24, 2026 |
| Dai Junyi | 11,250,000 | 8.44% | 13D (active) amendment | Jun 24, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INDP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hrt Financial LP | 206,077 | 0.15% | $618 | New | 0.00% |
| Geode Capital Management, LLC | 56,470 | 0.04% | $169.41K | +29,463 | 0.00% |
| Jane Street Group, LLC | 53,811 | 0.04% | $161.43K | New | 0.00% |
| Vanguard Capital Management LLC | 33,652 | 0.03% | $100.96K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 13,967 | 0.01% | $41.90K | New | 0.00% |
| Millennium Management LLC | 11,586 | 0.01% | $34.76K | New | 0.00% |
| Morgan Stanley | 8,936 | 0.01% | $26.81K | +6,239 | 0.00% |
| UBS Group AG | 478 | 0.00% | $1.43K | New | 0.00% |
| SBI Securities Co., Ltd. | 17 | 0.00% | $51 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 9 | 0M | 0.3% | 6 / 2 | 0 / 2 | 0M | 0M |
| Q1 2026 | 6 | 0M | 0.1% | 4 / 0 | 1 / 2 | 0M | 0M |
| Q4 2025 | 4 | 0M | 0.0% | 0 / 2 | 1 / 1 | 0M | 0M |
| Q3 2025 | 5 | 0M | 0.0% | 2 / 2 | 1 / 2 | 0M | 0M |
| Q2 2025 | 5 | 0M | 0.0% | 5 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of INDP | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 17,640 | 0.01% | $31.05K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 9,142 | 0.01% | $27.43K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 3,929 | 0.00% | $6.92K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 462 | 0.00% | $813 | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jeffrey A. Meckler | Co-Chief Executive Officer, Director | 229,929 | 0.17% | Feb 13, 2026 |
| Michael James Newman | CSO and Director | 1,469,430 | 1.10% | Dec 29, 2025 |
| Junyi Dai | Chief Executive Officer | 11,250,000 | 8.44% | Apr 2, 2026 |
| Walt Addison Linscott | Chief Operating Officer | 54,426 | 0.04% | Dec 29, 2025 |
| Nir Sassi | Chief Financial Officer | 26,758 | 0.02% | Dec 29, 2025 |
| Qinglai Lu | Director | – | – | Apr 20, 2026 |
| David E. Lazar | Director | 0 | – | Mar 24, 2026 |
| Jerome D. Jabbour | Director | – | – | Feb 27, 2026 |
| Matthew Charles McMurdo | Director | 25,000 | 0.02% | Feb 26, 2026 |
| Avraham Ben-Tzvi | Director | 25,100 | 0.02% | Jan 22, 2026 |
| David Natan | Director | 0 | – | Jan 22, 2026 |
| Hila Karah | Director | – | – | Jun 11, 2025 |
| Mark John Gilbert | Director | – | – | Jun 11, 2025 |
| Anthony J. Maddaluna | Director | 670 | 0.00% | Jun 11, 2025 |
| Roger Pomerantz | Director | – | – | Jun 11, 2025 |
| Robert Martell | Director | – | – | Jun 11, 2025 |
| William B. Hayes | Director | – | – | Jun 11, 2025 |
| LION VENTURES Ltd SINO | 10% owner | 38,895,000 | 29.19% | Apr 2, 2026 |
| Yun Yao | 10% owner | 41,991,000 | 31.51% | Apr 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Avraham Ben-Tzvi Director | Jan 20, 2026 | Award | +25,000 | – | – | 25,100 |
| Michael James Newman CSO and Director | Dec 22, 2025 | Award | +52,204 | $2.03 | $105.97K | 101,074 |
| Walt Addison Linscott Chief Operating Officer | Dec 22, 2025 | Award | +54,421 | $2.03 | $110.47K | 54,426 |
| Jeffrey A. Meckler Co-Chief Executive Officer, Director, 10% owner | Dec 22, 2025 | Award | +216,617 | $2.03 | $439.73K | 229,929 |
| Nir Sassi Chief Financial Officer | Dec 22, 2025 | Award | +26,758 | $2.03 | $54.32K | 26,758 |
| Jeffrey A. Meckler Chief Executive Officer, Director | Jul 27, 2025 | Award | +6,068 | $8.30 | $50.36K | 13,312 |
| Jeffrey A. Meckler CEO and Director | Nov 25, 2024 | Award | +42,553 | $1.18 | $50.21K | 202,859 |
| Jeffrey A. Meckler CEO and Director | Aug 8, 2024 | Award | +84,932 | $1.83 | $155.43K | 160,306 |
| Glen R. Anderson 10% owner | Aug 14, 2023 | Buy | +23,934 | $2.34 | $56.01K | 1,190,400 |
| Glen R. Anderson 10% owner | Aug 11, 2023 | Buy | +35,064 | $2.12 | $74.34K | 1,166,466 |
| Glen R. Anderson 10% owner | Aug 10, 2023 | Buy | +44,354 | $1.94 | $86.05K | 1,131,402 |
| Boyan Vesselinov Litchev Chief Medical Officer | Dec 1, 2022 | Buy | +500 | $1.87 | $935 | 1,150 |
| Boyan Vesselinov Litchev Chief Medical Officer | Nov 22, 2022 | Buy | +500 | $1.83 | $915 | 650 |
| Jeffrey A. Meckler CEO and Director | Nov 21, 2022 | Buy | +9,600 | $1.90 | $18.24K | 75,374 |
| Jeffrey A. Meckler CEO and Director | Nov 18, 2022 | Buy | +400 | $1.76 | $704 | 65,774 |
| Jeffrey A. Meckler CEO and Director | Sep 8, 2022 | Buy | +10,308 | $2.80 | $28.86K | 65,374 |
| Walt Addison Linscott Chief Business Officer | Sep 7, 2022 | Buy | +150 | $2.62 | $393 | 150 |
| Jeffrey A. Meckler CEO and Director | Sep 7, 2022 | Buy | +8,632 | $2.57 | $22.18K | 55,066 |
| Jeffrey A. Meckler CEO and Director | Sep 6, 2022 | Buy | +1,060 | $2.44 | $2.59K | 46,434 |
| Jeffrey A. Meckler CEO and Director | Jun 6, 2022 | Buy | +19,727 | $2.63 | $51.88K | 45,374 |
| Boyan Vesselinov Litchev Chief Medical Officer | Mar 2, 2022 | Buy | +50 | $4.09 | $205 | 150 |
| Michael James Newman CSO and Director, 10% owner | Feb 1, 2022 | Sale(10b5-1 plan) | −14,130 | $5.00 | $70.65K | 1,368,356 |
| Boyan Vesselinov Litchev Chief Medical Officer | Jan 31, 2022 | Buy | +100 | $4.65 | $465 | 100 |
| Michael James Newman CSO and Director, 10% owner | Jan 31, 2022 | Sale(10b5-1 plan) | −5,870 | $5.00 | $29.35K | 1,382,486 |
| Jeffrey A. Meckler CEO and Director | Nov 18, 2021 | Buy | +11,187 | $5.82 | $65.11K | 25,647 |
| Jeffrey A. Meckler CEO and Director | Sep 14, 2021 | Buy | +12,000 | $7.00 | $84.00K | 14,460 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.